

A4



WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4: C07H 15/12, C12P 21/00, 19/34 C12N 15/00, 7/00, 1/20 C12Q 1/68, C07K 13/00		(11) International Publication Number: WO 89/09777
A1		(43) International Publication Date: 19 October 1989 (19.10.89)
(21) International Application Number: PCT/US89/01473		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).
(22) International Filing Date: 7 April 1989 (07.04.89)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(30) Priority data: 179,387 US 249,584 US 26 September 1988 (26.09.88)		
(71) Applicant: ARCH DEVELOPMENT CORPORATION (US/US); 1115-25 East 58th Street, Chicago, IL 60637 (US).		
(72) Inventor: SUKHATHI, Vikas, P.; 1511 East 56th Street, Chicago, IL 60637 (US).		
(74) Agent: MEINERT, M. C.; Marshall, O'Toole, Gerstein, Murray & Bicknell, Two First National Plaza, Ste. 2100, Chicago, IL 60603 (US).		
(54) Title: METHODS AND MATERIALS RELATING TO DNA BINDING PROTEINS		
(57) Abstract DNA sequences associated with regulation of early stages of cell growth are described. Illustratively provided are human and mouse origin DNA sequence encoding early growth regulatory ("Egr") proteins which include "zinc finger" regions of the type involved in DNA binding. Immunological methods and materials for detection of Egr proteins and hybridization methods and materials for detection and quantification of Egr protein related nucleic acids are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

- |                                 |                      |                             |
|---------------------------------|----------------------|-----------------------------|
| AT Austria                      | FR France            | ML Mali                     |
| AU Australia                    | GA Gabon             | MR Mauritania               |
| BB Barbados                     | GB United Kingdom    | MY Malaysia                 |
| BE Belgium                      | HU Hungary           | NL Netherlands              |
| BG Bulgaria                     | IT Italy             | NO Norway                   |
| BJ Benin                        | JP Japan             | RO Romania                  |
| BR Brazil                       | KR Republic of Korea | SD Sudan                    |
| CF Central African Republic     | LI Liechtenstein     | SE Sweden                   |
| CG Congo                        | LK Sri Lanka         | SN Senegal                  |
| CH Switzerland                  | LJ Luxembourg        | SU Soviet Union             |
| CM Cameroon                     | LU Luxembourg        | TD Chad                     |
| DE Germany, Federal Republic of | MC Monaco            | TG Togo                     |
| DK Denmark                      | MG Madagascar        | US United States of America |
| FI Finland                      |                      |                             |

BEST AVAILABLE COPY

BEST AVAILABLE COPY

- 1 -

"METHODS AND MATERIALS RELATING TO  
DNA BINDING PROTEINS"

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation-in-part application of  
co-pending U.S. Patent Application Serial No. 179,587,  
filed April 8, 1988.

BACKGROUND OF THE INVENTION

The present invention relates generally to DNA  
binding regulatory proteins and more particularly to DNA  
sequences encoding early growth regulatory proteins  
possessing histidine-cysteine "zinc finger" DNA binding  
domains, to the polypeptide products of recombinant  
expression of these DNA sequences, to peptides and poly-  
peptides whose sequences are based on amino acid  
sequences deduced from these DNA sequences, to anti-  
bodies specific for such proteins and peptides, and to  
procedures for detection and quantification of such pro-  
teins and nucleic acids related thereto.

Among the most significant aspects of mam-  
malian cell physiology yet to be elucidated is the  
precise manner in which growth factors (e.g., hormones,  
neurotransmitters and various developmental and  
differentiation factors) operate to effect the regula-  
tion of cell growth. The interaction of certain growth  
factors with surface receptors of resting cells appears  
to rapidly induce a cascade of biochemical events  
thought to result in nuclear activation of specific  
growth related genes, followed by ordered expression of  
other genes. Analysis of sequential activation and  
expression of genes during the transition from a resting  
state ("G<sub>0</sub>") to the initial growing state ("G<sub>1</sub>") has  
been the subject of substantial research. See, gener-

- 2 -

ally, Lau et al., Proc. Nat'l. Acad. Sci. (USA), 84,  
1182-1186 (1987). Much of this research has involved  
analysis of the expression of known genes encoding sus-  
pected regulatory proteins (such as the proto-oncogenes,  
c-fos and c-myc) following mitogen stimulation. An  
alternative approach has involved attempts to identify  
genes activated by mitogenic stimuli through differen-  
tial screening of cDNA libraries prepared from resting  
cells following exposure to serum and specific growth  
factors. See, e.g., Lau et al., EMBO Journal, 4,  
3145-3151 (1985). See also, Cochran et al., Cell, 33,  
939-947 (1983), relating to the cloning of gene  
sequences apparently regulated by platelet derived  
growth factor.

Of interest to the background of the invention  
is the continuously expanding body of knowledge regard-  
ing structural components involved in the binding of  
regulatory proteins to DNA. Illustratively, the so-  
called receptor proteins are believed to bind to DNA by  
means of zinc ion stabilized secondary structural  
fingers premised on folding of continuous amino acid  
sequences showing high degrees of conservation of  
cysteines and histidines and hydrophobic residues. See,  
e.g., Gehring, TIBS, 12, 399-402 (1987). For example, a  
"zinc finger" domain or motif, present in Xenopus  
transcription factor IIRa (TF IIRa), as well as the  
Drosophila Kruppel gene product and various yeast  
proteins, involves "repeats" of about 30 amino acid  
residues wherein pairs of cysteine and histidine  
residues are coordinated around a central zinc ion and  
are thought to form finger-like structures which make  
contact with DNA. The histidine-cysteine (or "CC-HH")  
zinc finger motif, as opposed to a cysteine-cysteine  
("CC-CC") motif of steroid receptors, is reducible to a  
consensus sequence represented as C-X<sub>2</sub>-4-C-X<sub>3</sub>-F-X<sub>5</sub>-L-X<sub>2</sub>-  
H-X<sub>3</sub>-H wherein C represents cysteine, H represents

histidine, F represents phenylalanine, L represents leucine and X represents any amino acid. (See, Klug et al. TIBS, 12, 464-469 (1987); Blumberg et al., Nature, 328, 443-445 (1987); and Schuh et al., Cell, 47, 1025-1032 (1986).]

Of particular interest to the background of the invention is the recent report of Chowdhury et al., Cell, 48, 771-778 (1987), relating to an asserted "family" of genes encoding proteins having histidine-cysteine finger structures. These genes, designated "mkr1" and "mkr2", appear to be the first such isolated from mammalian tissue and are not correlated to any early growth regulatory events.

There continues to exist a need in the art for information concerning the primary structural conformation of early growth regulatory proteins, especially DNA binding proteins, such as might be provided by knowledge of human and other mammalian DNA sequences encoding the same. Availability of such DNA sequences would make possible the application of recombinant methods to the large scale production of the proteins in procaryotic and eukaryotic host cells, as well as DNA-DNA and DNA-RNA hybridization procedures for the detection, quantification and/or isolation of nucleic acids associated with these and related proteins. Possession of such DNA-binding proteins and/or knowledge of the amino acid sequences of the same would allow, in turn, the development of monoclonal and polyclonal antibodies thereto (including antibodies to protein fragments or synthetic peptides modeled thereon) for use in immunological methods for the detection and quantification of early growth regulatory proteins in fluid and tissue samples as well as for tissue specific delivery of substances such as labels and therapeutic agents to cells expressing the proteins. In addition, DNA probes based on the DNA sequences for these mammalian early growth

regulatory proteins may be of use in detecting gene markers used for the diagnosis of those clinical disorders which are linked to the marker genes.

#### BRIEF SUMMARY OF THE INVENTION

The present invention provides novel purified and isolated DNA sequences encoding mammalian early growth regulatory ("Egr") proteins which comprise one or more histidine-cysteine zinc finger amino acid sequences putatively providing DNA binding (and hence DNA replication or transcription regulatory) capacity. In presently preferred forms, novel DNA sequences of the invention comprise genomic and cDNA sequences encoding human and mouse early growth regulatory proteins. Alternate DNA forms, such as "manufactured" DNA, prepared by partial or total chemical synthesis from nucleotides, are also within the contemplation of the invention.

Operative association of Egr-encoding DNA sequences provided by the invention with homologous or heterologous species expression control DNA sequences, such as promoters, operators, regulators and the like, allows for in vivo and in vitro transcription to form messenger RNA which, in turn, is susceptible to translation to provide Egr proteins in large quantities. In one presently preferred DNA expression system practiced according to the invention, Egr-encoding DNA is operatively associated with a bacteriophage T3 or T7 RNA promoter DNA sequence allowing for in vitro transcription and translation in a cell free system. Incorporation of novel DNA sequences of the invention into procaryotic and eucaryotic host cells by standard transformation and transfection processes involving suitable viral and circular DNA plasmid vectors is also within the contemplation of the invention and is expected to

- 5 -

provide useful proteins in quantities heretofore unavailable from natural sources. Illustratively, fragments of DNA encoding Egr protein of the invention have been incorporated in plasmid vectors resulting in expression by transformed *E. coli* hosts of fusion proteins sharing immunological characteristics of Egr protein. Use of mammalian host cells is expected to provide for such post-translational modifications (e.g., truncation, glycosylation, and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention.

Also provided by the present invention are novel, presumptively mitogen sensitive, DNA sequences involved in regulation of the transcription of Egr-encoding DNA, which sequences are expected to have utility in the efficient recombinant expression of Egr proteins as well as proteins encoded by other structural genes. In addition, the DNA sequences may be used as probes to detect the presence or absence of gene markers used for the diagnosis of clinical disorders linked to those gene markers.

Novel polypeptide products of the invention include polypeptides having the primary structural conformation (i.e., amino acid sequence) of Egr proteins or fragments thereof, as well as synthetic peptides, analogs thereof, assembled to be partially or wholly duplicative of amino acid sequences extant in Egr proteins. Proteins, protein fragments, and synthetic peptides of the invention are expected to have therapeutic, diagnostic, and prognostic uses and also to provide the basis for preparation of monoclonal and polyclonal antibodies specifically immunoreactive with Egr proteins, as well as to provide the basis for the production of drugs for use as competitive inhibitors or potentiators of Egr. Preferred protein fragments and

- 6 -

synthetic peptides of the invention include those duplicating regions of Egr proteins which are not involved in DNA binding functions (i.e., regions other than the zinc fingers). Most preferred are peptides which share at least one continuous or discontinuous antigenic epitope with naturally occurring Egr proteins.

Antibodies of the invention preferably bind with high immunospecificity to Egr proteins, fragments, and peptides, preferably recognizing epitopes which are not common to other proteins, especially other DNA binding proteins.

Also provided by the present invention are novel procedures for the detection and/or quantification of Egr proteins and nucleic acids (e.g., DNA and mRNA) specifically associated therewith. Illustratively, antibodies of the invention may be employed in known immunological procedures for quantitative detection of Egr proteins in fluid and tissue samples. Similarly, DNA sequences of the invention (particularly those having limited homology to other DNAs encoding DNA binding proteins) may be suitably labelled and employed for the quantitative detection of mRNA encoding the proteins. Information concerning levels of Egr mRNA may provide valuable insights into growth characteristics of cells.

Among the multiple aspects of the present invention, therefore, is the provision of (a) novel purified and isolated Egr-encoding DNA sequences set out in Figures 1A, 3, and 4 as well as (b) Egr-encoding DNA sequences which hybridize thereto under hybridization conditions of the stringency equal to or greater than the conditions described herein and employed in the initial isolation of DNAs of the invention, and (c) synthetic or partially synthetic DNA sequences encoding the same, or allelic variant, or analog Egr polypeptides

- 7 -

which employ, at least in part, degenerate codons. Correspondingly provided are vital or circular plasmid DNA vectors incorporating such DNA sequences and pro-caryotic and eucaryotic host cells transformed or trans-fected with such DNA sequences and vectors as well as novel methods for the recombinant production of Egr proteins through cultured growth of such hosts and iso-lation from the hosts or their culture media.

Preferred polypeptide products of the inven-tion include those wholly or partially duplicating the deduced sequence of the amino acid residues set out in Figures 1A and 3 (i.e., mouse "Egr-1" and human "EGR2"). Other preferred polypeptides include fusion proteins such as cro-8-galactosidase/Egr-1 and bovine growth hormone/Egr-1.

Presently preferred antibodies of the inven-tion include those raised against synthetic peptides partially duplicating deduced Egr amino acid sequences of Figures 1A and 3 (e.g., the synthetic peptides H-L-R-Q-K-D-K-K-A-D-K-S-C, the first 12 amino acid residues of which duplicate mouse Egr-1 residues 416-427 with the last cysteine added for coupling to KLH; and C-G-R-K-F-A-R-S-D-E-R-K-R-H-T-K-I duplicating mouse Egr-1 residues 399-415). The antisera against the first peptide is designated VPS10 and comprises a preferred antibody of the invention.

As employed herein, the term "early growth regulatory protein" shall mean and include a mammalian DNA binding protein encoded by DNA whose transcription temporally corresponds to cellular events attending the G<sub>0</sub>/G<sub>1</sub> growth phase transition. As employed herein, "histidine-cysteine zinc finger amino acid sequence" shall mean and include the following sequence of amino acids C-X<sub>2</sub>-4-C-X<sub>3</sub>-F-X<sub>5</sub>-L-X<sub>2</sub>-H-X<sub>3</sub>-H wherein C represents cysteine, H represents histidine, F represents phenyl-alanine, L represents lysine, and X represents an amino acid.

- 8 -

Other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description thereof which includes numerous illustrative examples of the practice of the invention, reference being made to the drawing wherein:

Figure 1A provides a 3086 base nucleotide sequence for a mouse Egr-1 DNA clone as well as a deduced sequence of 533 amino acid residues for the protein; Figure 1B provides a partial restriction map of Egr-1 DNA clones together with information concerning the position of the protein coding sequence and the locus of amino acids providing for histidine-cysteine zinc fingers;

Figure 2 provides an amino acid sequence alignment of the DNA binding domain of mouse Egr-1 in comparison with a zinc finger consensus sequence, with the Drosophila Kruppel sequence and with the "finger 2" sequence of Xenopus TFIIIA protein;

Figure 3 provides a 2820 base nucleotide sequence for a human EGR2 cDNA clone as well as a deduced sequence of 456 amino acids for the protein;

Figure 4 provides a 1200 base nucleotide sequence of a mouse Egr-1 genomic clone, specifically illustrating the 5' non-transcribed regulatory region thereof comprising bases -935 through +1; and

Figure 5 provides a restriction map and organization of the mouse Egr-1 genomic clone mgEgr-1.1 and a comparison to mouse Egr-1 cDNA.

#### DETAILED DESCRIPTION

The following examples illustrate practice of the invention. Example 1 relates to the preparation and structural analysis of cDNA for mouse Egr-1. Example 2 relates to confirmation of the presence of an Egr DNA sequence on human chromosome 5. Example 3 relates to the in vitro transcription and translation of mouse

- 9 -

Egr-1 cDNA. Example 4 relates to production of antibodies according to the invention. Example 5 relates to the isolation and characterization of genomic DNA which encodes mouse Egr-1. Example 6 relates to the isolation and characterization of cDNA encoding human Egr2. Example 7 relates to preparation, in an *E. coli* host, of a recombinant fusion protein including a portion of the deduced amino acid sequence of mouse Egr-1. Example 8 relates to use of DNA probes of the invention in the quantitative detection of EGR1 mRNA.

These examples are for illustrative purposes only and are not intended in any way to limit the scope of the invention.

#### EXAMPLE 1

##### Preparation and Structural Analysis of cDNA for Mouse Egr-1

Isolation of DNA encoding a mammalian early growth regulatory protein including one or more histidine-cysteine zinc finger amino acid sequences was performed substantially according to the procedures described in Sukhatme et al., *Oncogene Research*, 1, 343-355 (1987), the disclosures of which are specifically incorporated by reference herein.

Balb/c 3T3 cells (clone A31) from the American Type Culture Collection were grown to confluence in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). The cells were rendered quiescent by reduction of the serum concentration to 0.75% for 48 hours. To induce the cells from quiescence into growth phase  $G_1$ , the medium was changed to 20% FCS with cycloheximide added to a final concentration of 10  $\mu\text{g/ml}$ .

RNA was extracted from Balb/c 3T3 cells harvested three hours after induction of quiescent cells by

- 10 -

20% FCS and 10  $\mu\text{g/ml}$  cycloheximide. A  $\lambda$ gt10 cDNA library was constructed from this mRNA according to the procedures of Huynh et al., *DNA Cloning*, Vol. 1, 49-78 (Glover, D., ed., IRL Press, 1985). This library was screened differentially with single stranded cDNA prepared from quiescent cells and from cells exposed to serum and cycloheximide for 3 hours. These  $^{32}\text{P}$ -labeled cDNA probes were prepared from poly  $A^+$  RNA as described in St. John, et al., *Cell*, 16, 443-452 (1979), except that 100  $\mu\text{Ci}$  of  $^{32}\text{P}$ -dCTP ( $>3000 \text{ Ci/mmol}$ ), 0.02 mM cold dCTP and 2-5  $\mu\text{g}$  of poly  $A^+$  RNA was used in each reaction. The mean size of the reverse transcribed probes, as assessed by alkaline agarose gel electrophoresis and subsequent autoradiography, was about 700 bases.

Replica filter lifts (GeneScreenPlus, NEN-DuPont) were prepared essentially as described by Benton et al., *Science*, 196, 180-192 (1977), and approximately  $3 \times 10^6$  cpm of  $^{32}\text{P}$ -cDNA were used per filter (90 mm diameter). Hybridizations were carried out at  $65^\circ\text{C}$  in 1% SDS, 10% dextran sulfate, and 1 M NaCl for a period of 16 hours. The filters were washed twice for twenty minutes each time, first at room temperature in 2 x SSC [Maniatis et al., *Molecular Cloning*, Cold Spring Harbor Laboratory (New York, 1982)], then at  $65^\circ\text{C}$  in 2 x SSC, 1% NaDodSO<sub>4</sub> and finally at  $65^\circ\text{C}$  in 0.2 x SSC.

Autoradiograms were prepared by exposing the blots for 18 hours at  $-70^\circ\text{C}$  with an intensifying screen.

A total of 10,000 cDNA clones from the Balb/c 3T3  $\lambda$ gt10 library were differentially screened. Seventy-eight clones were found to hybridize preferentially to single-stranded cDNA from fibroblasts stimulated for 3 hours with 20% FCS and cycloheximide as compared to single-stranded cDNA from quiescent cells. Inserts from these clones were cross-hybridized to each other, resulting in the sorting of forty clones into 7 cDNA families one of which was identified as *c-fos*.

Another cDNA clone, referred to as OC68, contained a 2.2 kb insert and was characterized further. This insert was subcloned into the Eco RI site of pUC13 and probes were generated for Northern blot analysis either from the insert or the corresponding pUC plasmid. Figure 1B illustrates a partial restriction digest map of the OC68 clone ("R" representing restriction sites for *NotI*) along with that of a shorter clone, OC19t. Two *RsaI* digestion fragments, derived from the 5' end of clone OC68 and each comprising approximately 130 base pairs, were labeled and employed to re-screen the above-described  $\lambda$ gt10 cDNA library, resulting in the recovery of a 3.1 kb clone, designated OC3.1, shown in figure 1B. This clone was sequenced according to the method of Sanger et al., *Proc. Nat'l. Acad. Sci. (USA)*, 74, 5463 (1977). The 3086 base pair sequence obtained is set forth in Figure 1A along with the deduced sequence of 533 amino acid residues for the protein encoded, designated mouse "Egr-1".

The deduced amino acid sequence shows a single long open reading frame with a stop codon (TAA) at position 1858. The most 5', in-frame, ATG, at position 259, is flanked by sequences that fulfill the Kozak criterion ( $\text{G}_{-1}\text{NN(ATG)G}$ ) (Kozak, *Nuc. Acids Res.*, 15, 8125-8131 (1987)). The sequence region upstream of this ATG is highly GC-rich and results in an absence of in-frame stop codons. The 3' untranslated region (UT) contains two "AT" rich regions (nucleotides 2550-2630 and 2930-2970). Similar sequences are found in the 3' UT regions of several lymphokine and proto-oncogene mRNAs, including granulocyte macrophage colony stimulating factor (GM-CSF), interleukin 1, interleukin 2, interleukin 3 (IL-3),  $\alpha$ ,  $\delta$ , and  $\gamma$  interferons, and c-fos, c-myc, and c-mycb [Shaw et al., *Cell*, 46, 659-667 (1986)]. These sequences may mediate selective mRNA degradation. The presence in the mouse Egr-1 transcript

of such regions is consistent with its short message half-life. Potential polyadenylation signals (AATAAA) are located at nucleotide positions 1865 and 3066, as well as at position 3053 (AATTA) [Wickens et al., *Science*, 226, 1045-1051 (1984)].

The deduced amino acid sequence predicts a polypeptide of 533 amino acids with a molecular weight of 56,596. Based on structural considerations, namely a central region containing zinc fingers (described below), the Egr-1 protein can be divided into three domains. The N-terminal portion (amino acid residues 2 to 331) is rich in proline (14.2%) and serine (16%) residues with 7.9% alanines and 7.9% threonines. The C-terminal region (residues 417 to 533) also contains a very high proportion of prolines and serines (15.4 and 26.5%, respectively) and 10.3% alanines and 11.1% threonines. The large number of proline residues leads to a secondary structure that probably lacks  $\alpha$ -helices. The central portion of the Egr-1 protein consists of three tandem repeat units of 28-30 amino acids, with the first unit starting at position 332. Each unit conforms almost exactly to the consensus sequence  $\text{TCX}_3\text{F}_3\text{XCX}_2\text{-}_4\text{CX}_3\text{FX}_5\text{IX}_2\text{HX}_3\text{H}$  (see Figure 2), diagnostic of DNA binding zinc fingers [Berg, *Science*, 232, 485-486 (1986); Brown et al., *Nature*, 324, 215 (1986); and Brown et al., *FEBS Letters*, 186, 271-274 (1985)]. Furthermore, the Egr-1 fingers are connected by "H-C links" ( $\text{TC}_3\text{F}_3\text{FX}$ ) [Schuh et al., *Cell*, 47, 1025-1032 (1986)] found in the Xenopus TP11A gene (between fingers 1, 2, and 3), in the Drosophila Kruppel gap gene [Rosenberg et al., *Nature*, 319, 336-339 (1986)], and in genes from mouse and Xenopus that cross-hybridize to the Kruppel (Kf) finger domains: mkr1, mkr2 [Chowdhury et al., *Cell*, 48, 771-778 (1987)], and Xfin [Altamir et al., *EMBO Journal*, 6, 3065-3070 (1987)]. The sequence similarity amongst the Egr-1

- 13 -

fingers is 50-70%, whereas the sequence similarity between any of the Egr-1 fingers and those present in TFIIA, Kruppel, mkr1, mkr2 or Xfin is 35-40%. Outside of the finger domains, it is noteworthy that the Egr-1 and Kr proteins each contain a very high proportion of pro, ala, and ser residues [Schuh et al., *Cell*, 47, 1025-1032 (1986)]. However, there is no sequence similarity in these regions. Thus, Egr-1 and Kr are not homologous genes nor is Egr-1 related to mkr1, mkr2, Xfin, or TFIIA. The Kr gene contains thirteen copies of the hexanucleotide (ACAAA), or its complementary sequence, eight of which are located within 180 bp downstream from the Kr TATA box and five are in the 3' UT region. These sequences may serve as targets for other DNA binding proteins or in Kr gene autoregulation. The Egr-1 cDNA also contains nine copies of the ACAA sequence or its complement.

Following the work described above, Milbrandt [Science, 238, 797-799 (1987)], reported the isolation and sequence of a nerve growth factor (NGF) inducible cDNA (NGFI-A) from the rat pheochromocytoma PC12 line. A comparison of the deduced amino acid sequence of NGFI-A to that of mouse Egr-1 of Figure 1A reveals 98% sequence identity. Thus, mouse Egr-1 and rat NGFI-A are homologs. The putative initiation ATG chosen by Milbrandt corresponds to position 343 in the Figure 1A cDNA sequence, and is 84 nucleotides (28 amino acid residues) downstream of the ATG therein designated for translation initiation. Both ATGs have a purine at position -3 and a G at position +1 and the designation represented in Figure 1A of the more 5' ATG as the putative start codon is based on the experience of Kozak, *Nuc. Acids Res.*, 15, 8125-8131 (1987), even though the more 3' ATG is surrounded by the longer Kozak consensus sequence (CCG/ACCATGG). Translation of an *in vitro* generated RNA transcript, described *infra*, selects the more 5' ATG for initiation.

- 14 -

It is noteworthy that a major difference in the deduced sequences of mouse Egr-1 and rat NGFI-A resides in the sequence spanning residues 61-68 of Egr-1 and 33-43 of NGFI-A. The former includes the sequence N-S-S-S-S-T-S-S while the latter includes the sequence N-N-S-S-S-S-S-S-S, accounting for the 3 residue difference in length of the putative polypeptides which is not accounted for by the difference in designation of the transcript initiation signal.

#### EXAMPLE 2

Human Chromosome Gene Mapping  
To determine the human chromosomal localization of the gene corresponding to mouse Egr-1, the OC3.1 and OC19t cDNA clones were hybridized to a panel of rodent x human somatic cell hybrids. Southern blot analysis of the hybrid panel showed concordance between the presence of Egr-1 sequences and human chromosome 5. *In situ* hybridization to normal human metaphase chromosomes resulted in specific labeling only of chromosome 5, with the largest cluster of grains at 5q23-31. Specific labeling of these bands was also observed in hybridizations using an Egr-1 probe which does not contain finger sequences.

This localization is interesting in light of the non-random deletions [del(5q)] in human myeloid disorders (acute myelogenous leukemia) (AML), and myelodysplastic syndromes, that involve this chromosomal region. [Le Beau et al., *Science*, 221, 984-987 (1986); Deward et al., *Blood*, 66, 189-197 (1985); and Van den Berghe et al., *Cancer Genet. Cytogenet.*, 17, 189-255 (1985)]. Fifty percent of patients with therapy related AML show chromosome 5 abnormalities (interstitial deletions or monosomy) and cytogenetic analysis of the deletions has revealed that one segment, consisting of bands



- 15 -

5q23-31, is absent in the malignant cells of all patients who have aberrations of chromosome 5. These data suggest that loss of a critical DNA sequence leading to hemizyosity (or homozygosity) of a recessive allele may play an important role in the pathogenesis of these disorders, a mechanism substantiated for retinoblastoma. Although genes for a number of growth factors and receptors (IL-3, GM-CSF,  $\beta_2$ -adrenergic receptor, endothelial cell growth factor, CSF-1, c-fms, pDGF receptor) are clustered in or near this region, Egr-1 (by virtue of its zinc fingers) is the only member of this group with potential transcriptional regulatory activity. It is therefore possible that its absence could lead to deregulated cell growth.

EXAMPLE 3In Vitro Expression of Mouse Egr-1 cDNA

A 2.1 kb Apal/Apal fragment (comprising nucleotides 120-2224 of Figure 1A) was isolated from the OC3.1 DNA clone. This fragment includes the translation start (ATG) codon at nucleotide position 259 designated in Figure 1A. The fragment was blunt-ended with T4 DNA polymerase and cloned into the Bluescript vector KS M13(+) containing a T3/T7 bacteriophage promoter. The (T3) sense transcript was generated and in vitro translated in a standard rabbit reticulocyte lysate system (Promega Biotec, Madison, WI. 53711) including 35S methionine as a radiolabel. An analogous in vitro transcription system was developed using a BglII/BglII fragment of OC3.1 (including nucleotides 301-1958 and not including the translation start designated in Figure 1A). The T7 sense transcript was employed in the translation system. Differential characterization of translation products by autoradiographic SDS PAGE indicated that the ATG at nucleotide position 259 is preferred as

- 16 -

a translation start codon when all potential start sites are present.

5

EXAMPLE 4Preparation of Antibodies:

A first synthetic peptide based on the sequence of amino acid residues 416-427 of mouse Egr-1 was prepared and provided with a carboxy terminal cysteine residue. The peptide, H-L-R-Q-K-D-K-A-D-K-S-C, was coupled to KLH and employed to immunize New Zealand white rabbits. Animals were initially immunized with 100  $\mu$ g of the immunogen in Freund's Complete Adjuvant and every two weeks were boosted with 100  $\mu$ g of immunogen with Freund's Incomplete Adjuvant. Sera, designated VPS10, were isolated after 68 days and displayed an antibody titer of 1:12,800 based on reactivity with the antigen used to prepare the anti-sera.

A second synthetic peptide, based on residues 399 to 415 of mouse Egr-1, was prepared. The peptide, C-G-R-R-A-R-S-D-E-R-K-R-H-T-K-I, was coupled to KLH and used to immunize rabbits as above, resulting in the production of antisera (designated VPS2) with a titer of 1:400.

EXAMPLE 5Isolation of Genomic Mouse Egr-1 Clone and Characterization of Regulatory Regions

A mouse Balb/c 3T3 genomic library was prepared in a Stratagene (La Jolla, California) vector,  $\lambda$ FIX, according to the manufacturer's instructions and probed using 1% SDS, 1 M NaCl, and 10% dextran sulfate at 65°C with stringent final wash in 0.2 x SSC at 65°C with a 2.1 kb Apal/Apal fragment and a 3.1 kb Eco RI/Eco

- 17 -

RI fragment derived from digestion of pUC13 including the mouse Egr-1 clone OC3.1. One positive clone, from approximately 300,000 screened, was designated mEgr-1.1 and also hybridized to the extreme 5'-end 120 bp Eco RI-Apa I fragment from plasmid OC3.1.

A 2.4 kb Pvu-II-PvuII fragment and a 6.6 kb XbaI-XbaI fragment (see Figure 5) derived from the mEgr-1.1 clone were subcloned into the SmaI and XbaI sites of pUC13 and pUC18 respectively, and the resulting plasmids (designated as p2.4 and p6.6) were used for restriction mapping analysis of transcription initiation sites and for nucleotide sequencing. Marked in Figure 4, and listed in Table 1, are possible regulatory elements identified in the 5' flanking sequence of mEgr-1.1. A putative TATA motif (AATAA) is located 26 nucleotides upstream of the transcription start site. A "CCAAT" type sequence starts at nucleotide -337. Five different regions, each 10 nucleotides in length, located at -110, -342, -358, -374, and -412, are nearly identical to the inner core of the C-fos serum response element (Treisman, R., Cell, 46, 567 (1986)). Each has a 5-6 nucleotide AT rich stretch and is surrounded by the dinucleotide CC on the 5' side and GG on the other. Two potential TPA responsive elements (Lee, W., et al., Cell, 49, 741 (1987) and Angel, P., et al., Cell, 49, 729 (1987)) are located at nucleotides -610 and -867. Four consensus Sp1 (Briggs, M.R., et al., Science, 234, 47 (1986) binding sequences are at position -285, -649, -700 and -719. In addition, two sequences have been identified that might serve as CAMP response elements (Montminy, M.R., et al., Nature, 328, 175 (1987)) (-138 and -631).

- 18 -

TABLE 1  
Location and Identification of Potential Regulatory Elements

Element	Sequence <sup>1</sup>	Location <sup>2</sup>
5	TATA CCAAT	-26 to -22 -337 to -333
10	TPA CCAAT	
15	TPA CCAAT	
20	TPA Responsive Element (AP1 binding site) Consensus	
25	TPA CCAAT	
30	Sp1 binding site	
35	CAMP Response Element Consensus	

1. The underlined bases in the mouse Egr-1 gene sequence are those that do not match the consensus sequence.  
2. The location numbers refer to the nucleotides of the mouse Egr-1 gene as indicated in Figure 4.

To obtain the genomic sequence and the intron-exon gene structure, specific oligonucleotides (17-mers at positions 83, 122, 174, 200, 379, 543, 611, 659, 905, 920, 1000, 1200, 1400, 1600, 1800, 2100, 2353, 2650, 2825) of the OC3.1 cDNA sequence (see Figure 1A) were used as primers for double stranded sequencing of plasmids p2.4 and p6.6. Comparison of the Egr-1 genomic sequence to the Egr-1 cDNA sequence showed the Egr-1 gene consists of 2 exons and a single 700 bp intron (between nucleotide position 556 and 557 as numbered in Figure 1A and as shown in Figure 5). Both the 5' and 3' splice junction sequences (not shown) are in excellent agreement with the consensus boundary sequences. Mount, S.M., Nucleic Acids Res., 10, 459 (1982).

#### EXAMPLE 6

##### Isolation and Characterization of Human EGR2 CDNA

A human genomic placental library in the vector EMBL3, prepared by Dr. C. Westbrook of the University of Chicago according to procedures described in Frischauff et al., Jour. Mol. Biol., 170, 827-842 (1983), and a human leukocyte cosmid library prepared according to procedures described in Proc. Nat'l. Acad. Sci. (USA), 80, 5225-5229 (1983), were probed with the 2.1 kb ApaI fragment of OC3.1 (described in Example 5) using 1% SDS, 1 M NaCl and 10% dextrose sulfate at 50-55°C with a non-stringent final wash in 2 x SSC at 50-55°C. A single positive clone (designated HG6) was isolated from the first library and four clones (designated HG17, 18, 19 and 21, respectively) were isolated from the second library. A 6.6 kb SalI/EcoRI fragment of clone HG6 was found to hybridize with a 332 base pair HpaII/HpaII fragment of the mouse Egr-1 gene,

which letter fragment spans the putative zinc finger region. The 6.6 kb fragment, in turn, was employed to probe a cDNA library derived from human fibroblasts which have been stimulated for three hours with 20% fetal calf serum in the presence of 10 µg/ml cyclohexamide. About 10,000 clones were screened and the fifty positive clones obtained (designated "zap-1 through zap-50") are being subjected to nucleotide sequence analysis. Preliminary sequence analysis reveals that three clones, zap-2, zap-8, and zap-32, all encode the same transcript, namely a protein designated human EGR2, shown in Figure 3. Preliminary analysis indicates approximately 92% homology between mouse Egr-1 and human EGR2 polypeptides in the zinc finger regions, but substantially less homology in the amino and carboxy terminal regions. Chromosome mapping studies, similar to those described in Example 2, indicate that human chromosome 10, at bands q21-22, constitutes a locus for the human EGR2 gene.

The plasmid zap-32, containing the full length human EGR2 clone, was used as a probe in Southern blot analysis on DNAs from 58 unrelated Caucasians. It was found that Hind III detects a simple two-allele polymorphism with bands at either 8.0 kb (A1) or 5.6 kb and 2.4 kb (A2). No constant bands were detected. The frequency of A1 was 0.90 and that of A2 was 0.10. No polymorphisms were detected for Apa I, BamH I, Ban II, Bgl I, Bgl II, BstE II, Dra I, EcoR I, EcoR V, Hinc II, Msp I, Pst I, Pvu II, Rsa I, Sac I, and Tag I in 10 unrelated individuals. Co-dominant segregation of the Hind III RFLP was observed in four large kindreds with a total of more than 350 individuals.

These data will be useful in gene linkage studies for mapping genes for certain genetic disorders. For example, the gene responsible for the dominantly inherited syndrome, multiple endocrine

- 21 -

neoplasia, type 2A (MEN-2A) has been assigned by linkage to chromosome 10. Simpson, et al., Nature, 328, 528 (1987). Studies are currently underway to determine the linkage relationship between MEN-2A and EGR2 and are expected to be useful in cloning the MEN-2A gene as well as in serving as a diagnostic marker for the disease.

#### EXAMPLE 7

##### Recombinant Expression Of Fusion Proteins

A 322 base HpaII/HpaII fragment (comprising nucleotides 1231-1553) derived from the OC3.1 cloned DNA was treated with DNA polymerase to fill in the single stranded ends. This fragment was inserted in plasmid pEX3 (obtained from K. Stanley, European Molecular Biology Laboratory, Postfach 10.2209, 6900 Heidelberg, F.R.G.) digested with SmaI. Stanley, K.K., et al., EMBO J., 3, 1429 (1984). This insertion placed the Egr-1 encoding DNA fragment in the same reading frame as plasmid DNA encoding cro-galactosidase, allowing for the expression of a fusion protein comprising the amino terminal residues of cro-galactosidase and 108 residues of Egr-1 amino acids 325 to 432. This cro-galactosidase/Egr-1 fusion plasmid, designated pFIG, was used to transform *E. coli* NPI.

Induced (42°C) and un-induced (30°C) cultured cell lysates from growth of the transformed NPI cells were then analyzed by SDS-PAGE. Upon Coomassie stain analysis, only induced cell lysates included an approximately 108 kd product, indicating presence of the projected expression product. Western blot analysis, using the rabbit polyclonal anti-peptide antibody VPS10 (see Example 4) raised against H-L-R-Q-K-D-K-A-D-K-S-C, confirmed that the fusion protein product contained Egr sequences.

- 22 -

In a separate construction, a mouse Egr-1 insert, from plasmid OC3.1, was fused, in frame, to a plasmid containing sequences from bovine growth hormone according to the methods described in Slamon, D.J., et al., Science, 233, 347 (1986). The resultant plasmid, designated pV4, comprised a fusion protein containing a fusion gene coding for bovine growth hormone amino acids 1 to 192 and Egr-1 amino acids 2 to 533. This bGH/mouse Egr-1 DNA fusion plasmid, designated pV4, was expressed in *E. coli* and the resulting fusion protein, designated V4, was identified in Western blots by its reactivity with a bGH monoclonal antibody and its reactivity with VPS10 rabbit anti-Egr-1 peptide antiserum, prepared according to Example 4.

#### EXAMPLE 8

##### Determination of Egr Levels in Human Tumor and Non-Tumor Tissue

Using the mouse Egr-1 OC68 probe, Northern blot analyses were conducted to determine the levels of transcription of Egr protein encoding DNA in tumor versus surrounding normal tissue from resected human tumor specimens. The tumor samples were from lung (12), colon (7), colon mesastasis (1), bladder (1), rectal (1), giant cell (1), hepatoma (1), breast (1), MPF (malignant fibrous histiocytoma) (1), osteosarcoma (1) and rhabdomyosarcoma (1). In about 50% of these cases, there is markedly decreased (about three to ten-fold) expression of the Egr mRNA in tumor versus normal tissue. One implication of this finding is that Egr proteins of the invention may function as part of a negative regulatory pathway. In any event, it is clear that DNA sequences and antibodies of the invention are susceptible to use in differential diagnoses between tumorous and non-tumorous cell types.

It will be apparent from consideration of the foregoing illustrative examples that the present invention constitutes a substantial advance in the art and the achievement of a major goal in molecular biology, i.e., the characterization of genes which play a regulatory role in mammalian cell proliferation and differentiation. It will thus be understood that the information provided herein constitutes a basis for straightforward development of useful methods and materials not specifically the subject of the above examples. By way of illustration, possession of knowledge concerning the base sequence of cDNA and genomic DNA sequences encoding distinct mouse Egr-1 and human EGR2 early growth regulatory proteins comprising histidine-cysteine zinc finger amino acid sequences makes possible the isolation of other such structurally related proteins. The substantial homology between the zinc finger regions of Egr-1 and EGR2 coupled with lack of homology in other protein regions, when considered in light of the ability of Egr-1 probes to localize to human chromosome 5 while EGR2 probes localize to human chromosome 10, essentially assures the straightforward isolation of a human gene (provisionally designated "human EGR1") which encodes a protein more closely homologous to Egr-1 and a mouse gene (Egr-2) encoding a protein more closely homologous to EGR2.

While the above examples provide only limited illustration of *in vitro* and *in vivo* expression of DNA sequences of the invention, known recombinant techniques are readily applicable to development of a variety of procaryotic and eucaryotic expression systems for the large scale production of Egr proteins and even development of gene therapy regimens.

Knowledge of the specifically illustrated mouse Egr-1 and human EGR2 proteins of the invention has been demonstrated to provide a basis for preparation of

highly useful antibodies, also provides a wealth of information concerning the nature of protein-nucleic acid interactions which, in turn, constitutes a basis for determination of significant early growth regulatory events. For example, and by analogy to steroid receptor protein structures, analysis of the structure of regions flanking the zinc fingers of Egr-1 and EGR2 and related proteins of the invention is expected to allow for identification of substances which may interact with the proteins to alter their DNA interactive capacities and thus provide the basis for inhibition or augmentation of their regulatory functions. Moreover, information available concerning specific events of DNA interaction of Egr proteins of the invention will permit, e.g., identification and use of potential competitive inhibitors of these proteins.

Just as Egr encoding DNA of the invention is conspicuously susceptible to use in differentiation of human tumor and non-tumor cells, antibodies prepared according to the invention are expected to be useful in differential screening of cells based on relative cellular concentrations of mRNA expression products and in the determination of specific genes susceptible to regulation by such products.

Because numerous modifications and variations in the practice of the present invention are expected to occur to those skilled in the art, only such limitations as appear in the appended claims should be placed thereon.

- 25 -

WHAT IS CLAIMED IS

1. A purified and isolated DNA sequence encoding a mammalian early growth regulatory protein which comprises one or more histidine-cysteine zinc finger amino acid sequences.
2. The DNA sequence according to claim 1 encoding human EGR2 protein.
3. The DNA sequence according to claim 1 encoding mouse Egr-1 protein.
4. The DNA sequence according to claim 1 which is a cDNA sequence.
5. The DNA sequence according to claim 1 which is a genomic DNA sequence.
6. The DNA sequence according to claim 1 which is a wholly or partially synthetic DNA sequence.
7. The DNA sequence according to claim 1 operatively associated with an homologous or heterologous expression control DNA sequence.
8. The DNA sequence according to claim 1 selected from the group consisting of the DNA sequences set out in Figures 1A, 3, and 4.
9. A prokaryotic or eucaryotic host cell transformed or transfected with a DNA sequence comprising a DNA sequence according to claim 1 or 7.
10. A viral or circular DNA plasmid vector comprising a DNA sequence according to claim 1.

- 26 -

11. The viral or circular DNA plasmid vector according to claim 10 further comprising an expression control DNA sequence operatively associated with said early growth regulatory protein encoding DNA.
12. A method for the production of an early growth regulatory protein comprising:  
growing, in culture, a host cell transformed or transfected with a DNA sequence according to claim 1; and  
isolating from said host cell or culture the polypeptide product of the expression of said DNA sequence.
13. A method for the production of an early growth regulatory protein comprising:  
disposing a DNA sequence according to claim 1 in a cell free transcription and translation system; and  
isolating from said system the polypeptide product of the expression of said DNA sequence.
14. The polypeptide product of the in vitro or in vivo expression of part or all of a protein encoding region of a DNA sequence according to claim 1.
15. The polypeptide product according to claim 14 which is a fusion protein comprising part or all of a mammalian early growth regulatory protein which comprises one or more histidine-cysteine zinc finger amino acid sequences and part or all of a heterologous proteins.
16. The polypeptide product according to claim 15, which comprises a fusion of crot- $\beta$ -galactosidase and Egr-1 amino acid sequences or bovine growth hormone and Egr-1 amino acid sequences.

17. A purified and isolated mammalian early growth regulatory protein comprising one or more histidine-cysteine zinc finger amino acid sequences.

18. The protein according to claim 17 and having the amino acid sequence set out in Figure 1A.

19. The protein according to claim 17 and having the amino acid sequence set out in Figure 3.

20. A synthetic peptide duplicative of a sequence of amino acids present in a mammalian early growth regulatory protein comprising one or more histidine-cysteine zinc finger amino acid sequences and sharing at least one antigenic epitope of such protein.

21. The synthetic peptide of claim 20 and having an amino acid sequence partially duplicative of the amino acid sequence set out in Figure 1A.

22. The synthetic peptide of claim 20 and having an amino acid sequence partially duplicative of the amino acid sequence set out in Figure 3.

23. The synthetic peptide of claim 20 and further characterized as duplicative of an amino acid sequence not involved in DNA binding functions.

24. An antibody specifically immunoreactive with at least one epitope of a mammalian early growth regulatory protein comprising one or more histidine-cysteine zinc finger amino acid sequences.

25. The antibody according to claim 24 wherein said epitope is other than an epitope within the DNA binding functional region thereof.

26. The antibody according to claim 24 selected from the group consisting of monoclonal and polyclonal antibodies.

27. The antibody according to claim 24 capable of specifically binding with a proteinaceous material comprising an amino acid sequence duplicating an antigenic epitope within the following amino acid sequence:

H-L-R-Q-K-D-K-K-A-D-K-S-C.

28. The antibody according to claim 24

capable of specifically binding with a proteinaceous material comprising an amino acid sequence duplicating an antigenic epitope within the following amino acid sequence:

C-G-R-K-F-A-R-S-D-E-R-K-R-H-T-K-I.

29. A method for quantitative detection of a mammalian early growth regulatory protein comprising one or more histidine-cysteine zinc finger amino acid sequences based on the immunological reaction of the same with an antibody according to claim 24.

30. A method for quantitative detection within a sample of messenger RNA transcripts for mammalian early growth regulatory proteins comprising one or more histidine-cysteine zinc finger amino acid sequences comprising the step of hybridizing RNA within said sample with a DNA sequence partially or wholly duplicating a DNA sequence according to claim 1.

31. A method for quantitative detection within a sample of DNA encoding for mammalian early growth regulatory proteins comprising one or more histidine-cysteine zinc finger amino acid sequences comprising the step of hybridizing DNA within said sample with a DNA sequence partially or wholly duplicating a DNA sequence according to claim 1.

32. A method for detecting a disease genetically linked to a mammalian Egr gene comprising the step of quantitating mammalian early growth regulatory DNA sequences according to claim 1.

10 20 30 40 50 60  
GGGGAGCCGCCGCCGCGATTTCGCCGCCGCCGCCAGCTTCCGCCGCCGCCGAAGATCGGCCCC

70 80 90 100 110 120  
TGCCCCAGCCTCCGCCGCCAGCCCTGCGTCCACCACGGGCCGCCGCTACCGCCAGCCTGGG

130 140 150 160 170 180  
GGCCCCACCTACACTCCCCGCAGTGTGCCCTGCACCCCGCATGTAACCCGGCCAACCCCC

190 200 210 220 230 240  
GGCGAGTGTGCCCTCAGTAGCTTCGGCCCCGGGCTGCGCCCAACCAACATCAGTTCT

250 260 270 280 290 300  
CCAGCTCGCTGGTCCGGGATGGCAGCGGCCAAGGCCGAGATGCAATTGATGTCTCCGCTG  
MetAlaAlaAlaLysAlaGluMetGlnLeuMetSerProLeu

310 320 330 340 350 360  
CAGATCTCTGACCCGTTTCGGCTCCTTTCCCTCACTCACCCACCATGGACAACCTACCCAAA  
GlnIleSerAspProPheGlySerPheProHisSerProThrMetAspAsnTyrProLys

370 380 390 400 410 420  
CTGGAGGAGATGATGCTGCTGAGCAACGGGGCTCCCCAGTTCCTCGGTGCTGCCGGAACC  
LeuGluGluMetMetLeuLeuSerAsnGlyAlaProGlnPheLeuGlyAlaAlaGlyThr

FIGURE 1.1

SUBSTITUTE SHEET



SUBSTITUTE SHEET

430 440 450 460 470 480  
 CCAGAGGGCAGCGGCGGTAATAGCAGCAGCAGCACCAGCAGCGGGGCGGTGGTGGGGGC  
 ProGluGlySerGlyGlyAsnSerSerSerSerThrSerSerGlyGlyGlyGlyGlyGly  
 490 500 510 520 530 540  
 GGCAGCAACAGCGGCAGCAGCGCCTTCAATCCTCAAGGGGAGCCGAGCGAACAACCCTAT  
 GlySerAsnSerGlySerSerAlaPheAsnProGlnGlyGluProSerGluGlnProTyr  
 550 560 570 580 590 600  
 GAGCACCTGACCACAGAGTCCTTTTCTGACATCGCTCTGAATAATGAGAAGGCGATGGTG  
 GluHisLeuThrThrGluSerPheSerAspIleAlaLeuAsnAsnGluLysAlaMetVal  
 610 620 630 640 650 660  
 GAGACGAGTTATCCAGCCAAACGACTCGGTTGCCTCCCATCACCTATACTGGCCGCTTC  
 GluThrSerTyrProSerGlnThrThrArgLeuProProIleThrTyrThrGlyArgPhe  
 670 680 690 700 710 720  
 TCCCTGGAGCCCGCACCCAACAGTGGCAACACTTTGTGGCCTGAACCCCTTTTCAGCCTA  
 SerLeuGluProAlaProAsnSerGlyAsnThrLeuTrpProGluProLeuPheSerLeu  
 730 740 750 760 770 780  
 GTCAGTGGCCTCGTGAGCATGACCAATCCTCCGACCTCTTCATCCTCGGCGCCTTCTCCA  
 ValSerGlyLeuValSerMetThrAsnProProThrSerSerSerSerAlaProSerPro  
 790 800 810 820 830 840  
 GCTGCTTCATCGTCTTCTCTGCCTCCAGAGCCCGCCCTGAGCTGTGCCGTGCCGTCC  
 AlaAlaSerSerSerSerSerAlaSerGlnSerProProLeuSerCysAlaValProSer

FIGURE 1.2

SUBSTITUTE SHEET

850 860 870 880 890 900  
 AACGACAGCAGTCCCATCTACTCGGCTGCGCCACCTTTCCTACTCCCAACACTGACATT  
 AsnAspSerSerProIleTyrSerAlaAlaProThrPheProThrProAsnThrAspIle  
 910 920 930 940 950 960  
 TTTCTGAGCCCCAAAGCCAGGCCTTTCCTGGCTCGGCAGGCACAGCCTTGACGTACCCG  
 PheProGluProGlnSerGlnAlaPheProGlySerAlaGlyThrAlaLeuGlnTyrPro  
 970 980 990 1000 1010 1020  
 CCTCCTGCCTACCCTGCCACCAAAGGTGGTTTCCAGGTTCCCATGATCCCTGACTATCTG  
 ProProAlaTyrProAlaThrLysGlyGlyPheGlnValProMetIleProAspTyrLeu  
 1030 1040 1050 1060 1070 1080  
 TTTCCACAACAACAGGGAGACCTGAGCCTGGGCACCCAGACCAGAAGCCCTTCCAGGGT  
 PheProGlnGlnGlnGlyAspLeuSerLeuGlyThrProAspGlnLysProPheGlnGly  
 1090 1100 1110 1120 1130 1140  
 CTGGAGAACCGTACCCAGCAGCCTTCGCTCACTCCACTATCCACTATTAAAGCCTTCGCC  
 LeuGluAsnArgThrGlnGlnProSerLeuThrProLeuSerThrIleLysAlaPheAla  
 1150 1160 1170 1180 1190 1200  
 ACTCAGTCGGGCTCCAGGACTTAAAGGCTCTTAATACCACCTACCAATCCCAGCTCATC  
 ThrGlnSerGlySerGlnAspLeuLysAlaLeuAsnThrThrTyrGlnSerGlnLeuIle  
 1210 1220 1230 1240 1250 1260  
 AAACCCAGCCGCATGCGCAAGTACCCCAACCGGCCAGCAAGACACCCCCCATGAACGC  
 LysProSerGlyMetArgLysTyrProAsnArgProSerLysProProHisGluArg

FIGURE 1.3

**THIS PAGE BLANK (USPTO)**

SUBSTITUTE SHEET

1270 1280 1290 1300 1310 1320  
CCATATGCTTGCCCTGTCGAGTCCTGCGATCGCCGCTTTTCTCGCTCGGATGAGCTTACC  
ProTyrAlaCysProValGluSerCysAspArgArgPheSerArgSerAspGluLeuThr

1330 1340 1350 1360 1370 1380  
CGCCATATCCGCATCCACACAGGCCAGAAGCCCTTCCAGTGTGCAATCTGCATGCGTAAC  
ArgHisIleArgIleHisThrGlyGlnLysProPheGlnCysArgIleCysMetArgAsn

1390 1400 1410 1420 1430 1440  
TTCAGTCGTAGTGACCACCTTACCACCCACATCCGCACCCACACAGGCGAGAAGCCTTTT  
PheSerArgSerAspHisLeuThrThrHisIleArgThrHisThrGlyGluLysProPhe

1450 1460 1470 1480 1490 1500  
GCCTGTGACATTTGTGGGAGGAAGTTTGCCAGGAGTGATGAACGCAAGAGGCATACCAAA  
AlaCysAspIleCysGlyArgLysPheAlaArgSerAspGluArgLysArgHisThrLys

1510 1520 1530 1540 1550 1560  
ATCCATTTAAGACAGAAGGACAAGAAAGCAGACAAAAGTGTGGTGGCCTCCCCGGCTGCC  
IleHisLeuArgGlnLysAspLysLysAlaAspLysSerValValAlaSerProAlaAla

1570 1580 1590 1600 1610 1620  
TCTTCACTCTCTTCTTACCCATCCCCAGTGGCTACCTCCTACCCATCCCCCTGCCACCACC  
SerSerLeuSerSerTyrProSerProValAlaThrSerTyrProSerProAlaThrThr

1630 1640 1650 1660 1670 1680  
TCATTCCCATCCCCCTGTGCCCACTTCTACTCCTCTCCTGGCTCCTCCACCTACCCATCT  
SerPheProSerProValProThrSerTyrSerSerProGlySerSerThrTyrProSer

FIGURE 1.4

SUBSTITUTE SHEET

1690 1700 1710 1720 1730 1740  
CCTGCGCACAGTGGCTTCCCGTCGCGGTGAGTGGCCACCACCTTTGCTCCGTTCCACCT  
ProAlaHisSerGlyPheProSerProSerValAlaThrThrPheAlaSerValProPro

1750 1760 1770 1780 1790 1800  
GCTTTCCCCACCCAGGTCAGCAGCTTCCCGTCTGCGGGCGTCAGCAGCTCCTTCAGCACC  
AlaPheProThrGlnValSerSerPheProSerAlaGlyValSerSerSerPheSerThr

1810 1820 1830 1840 1850 1860  
TCAACTGGTCTTTCAGACATGACAGCGACCTTTTCTCCCAGGACAATTGAAATTTGCTAA  
SerThrGlyLeuSerAspMetThrAlaThrPheSerProArgThrIleGluIleCys

1870 1880 1890 1900 1910 1920  
AGGGAATAAAAGAAAGCAAAGGGAGAGGCAGGAAAGACATAAAAGCACAGGAGGGAAGAG

1930 1940 1950 1960 1970 1980  
ATGGCCGCAAGAGGGGCCACCTCTTAGGTGAGATGGAAGATCTCAGAGCCAAGTCCTTCT

1990 2000 2010 2020 2030 2040  
ACTCACGAGTAGAAGGACCGTTGGCCAACAGCCCTTTCACTTACCATCCCTGCCTCCCCC

2050 2060 2070 2080 2090 2100  
GTCCTGTTCCCTTTGACTTCAGCTGCCTGAAACAGCCATGTCCAAGTTCTTCACCTCTAT

FIGURE 1.5

**THIS PAGE BLANK (USPTO)**

SUBSTITUTE SHEET

2110 2120 2130 2140 2150 2160  
CCAAAGGACTTGATTTGCATGGTATTGGATAAATCATTTCAGTATCCTCTCCATCACATG

2170 2180 2190 2200 2210 2220  
CCTGGCCCTTGCTCCCTTCAGCGCTAGACCATCAAGTTGGCATAAAGAAAAAAATGGG

2230 2240 2250 2260 2270 2280  
TTTGGGCCCTCAGAACCCTGCCCTGCATCTTTGTACAGCATCTGTGCCATGGATTTTGTT  
2290 2300 2310 2320 2330 2340  
TTCCTTGGGGTATTCTTGATGTGAAGATAATTTGCATACTCTATTGTATTATTTGGAGTT

2350 2360 2370 2380 2390 2400  
AAATCCTCACTTTGGGGGAGGGGGGAGCAAAGCCAAGCAAACCAATGATGATCCTCTATT

2410 2420 2430 2440 2450 2460  
TTGTGATGACTCTGCTGTGACATTAGGTTTGAAGCATTTTTTTTTTCAAGCAGCAGTCCT

2470 2480 2490 2500 2510 2520  
AGGTATTAACTGGAGCATGTGTCAGAGTGTGTTCCGTTAATTTTGTAATACTGGCTCG

FIGURE 1.6

SUBSTITUTE SHEET

2530 2540 2550 2560 2570 2580  
ACTGTAACTCTCACATGTGACAAAGTATGGTTTGTGTTGGTGGGTTTTGTTTTGAGAAT

2590 2600 2610 2620 2630 2640  
TTTTTTGCCCGTCCCTTTGGTTTCAAAGTTTCACGTCTTGGTGCCTTTTGTGTGACACG

2650 2660 2670 2680 2690 2700  
CCTTCCGATGGCTTGACATGCGCAGATGTGAGGGACACGCTCACCTTAGCCTTAAGGGGG  
2710 2720 2730 2740 2750 2760  
TAGGAGTGATGTGTTGGGGGAGGCTTGAGAGCAAAAACGAGGAAGAGGGCTGAGCTGAGC

2770 2780 2790 2800 2810 2820  
TTTCGGTCTCCAGAATGTAAGAAGAAAAATTTAAACAAAAATCTGAACTCTCAAAGTC

FIGURE 1.7

**THIS PAGE BLANK (USPTO)**

SUBSTITUTE SHEET

2830	2840	2850	2860	2870	2880
TATTTTTCTAAACTGAAAATGTAAATTTATACATCTATTTCAGGAGTTGGAGTGTGTGGT					
2890	2900	2910	2920	2930	2940
TACCTACTGAGTAGGCTGCAGTTTTTGTATGTTATGAACATGAAGTTCATTATTTTGTGG					
2950	2960	2970	2980	2990	3000
TTTTATTTTACTTTGTACTTGTGTTTGCTTAAACAAAGTAACCTGTTTGGCTTATAAACA					
3010	3020	3030	3040	3050	3060
CATTGAATGCGCTCTATTGCCCATGGGATATGTGGTGTGTATCCTTCAGAAAAATTAAAA					
3070	3080				
GGAAAAATAAAAAAAAAAAAAAAAAAAAA					

FIGURE 1.8

SUBSTITUTE SHEET




FIGURE 1B

**THIS PAGE BLANK (USPTO)**



10/21

PCT/US89/01473

## SUBSTITUTE SHEET

"Zinc finger"  
consensus sequence

T G E<sup>R</sup><sub>K</sub> P<sup>F</sup><sub>Y</sub> X C X X X X C X X X F X X X X L X X H X X X H

Murine Egr-1

P H E R P Y A C P V E S C D R R F S R S D E L T R H I R I H  
T G Q K P F Q C - - R I C M R N F S R S D H L T T H I R T H  
T G E K P F A C - - D I C G R K F A R S D E R K R H T K I H

Drosophila Kruppel

S R D K S F T C K I - - C S R S F G Y K H V L Q N H E R T H  
T G E K P F E C P E - - C D K R F T R D H H L K T H M R L H  
T G E K P Y H C S H - - C D R Q F V Q V A N L R R H L R V H  
T G E R P Y T C E I - - C D G K F S D S N Q L K S H M L V H

Xenopus TFIIIA  
(finger 2)

T G E K P F P C K E E G C E K G F T S L H H L T R H S L T H

FIGURE 2

11/21

PCT/US89/01473

## SUBSTITUTE SHEET

10 20 30 40 50 60  
TTTTTTTTTTTGGTGTGTGTGGTGGTTGTTTTTAAGTGTGGAGGGCAAAGGAGATACCA

70 80 90 100 110 120  
TCCCAGGCTCAGTCCAACCCCTCTCCAAAACNGTGTCTTTTCTGACACTCCAGGTAGCGA

130 140 150 160 170 180  
GGGAGTTGGGTCTCCAGGTTGTGCGAGGAGCAAATGATGACCGCCAAGGCCGTAGACAAA  
MetMetThrAlaLysAlaValAspLys

190 200 210 220 230 240  
ATCCCAGTAACTCTCAGTGGTTTTGTGCACCAGCTGTCTGACAACATCTACCCGGTGGAG  
IleProValThrLeuSerGlyPheValHisGlnLeuSerAspAsnIleTyrProValGlu

250 260 270 280 290 300  
GACCTCGCCGCCACGTCCGGTGACCATCTTTCCCAATGCCGAAGTGGGAGGCCCTTTGAC  
AspLeuAlaAlaThrSerValThrIlePheProAsnAlaGluLeuGlyGlyProPheAsp

310 320 330 340 350 360  
CAGATGAACGGAGTGGCCGGAGATGGCATGATCAACATTGACATGACTGGAGAGAAGAGG  
GlnMetAsnGlyValAlaGlyAspGlyMetIleAsnIleAspMetThrGlyGluLysArg

FIGURE 3.1

**THIS PAGE BLANK (USPTO)**

SUBSTITUTE SHEET

370 380 390 400 410 420  
 TCGTTGGATCTCCCATATCCCAGCAGCTTTGCTCCCGTCTCTGCACCTAGAAACCAGACC  
 SerLeuAspLeuProTyrProSerSerPheAlaProValSerAlaProArgAsnGlnThr  
 430 440 450 460 470 480  
 TTCATTACATGGGCAAGTTCTCCATTGACCCACAGTACCCTGGTGCCAGCTGCTACCCA  
 PheThrTyrMetGlyLysPheSerIleAspProGlnTyrProGlyAlaSerCysTyrPro  
 490 500 510 520 530 540  
 GAAGGCATAATCAATATTGTGAGTGCAGGCATCTTGCAAGGGGTCACTTCCCCAGCTTCA  
 GluGlyIleIleAsnIleValSerAlaGlyIleLeuGlnGlyValThrSerProAlaSer  
 550 560 570 580 590 600  
 ACCACAGCCTCATCCAGCGTCACCTCTGCCTCCCCAACCCACTGGCCACAGGACCCCTG  
 ThrThrAlaSerSerSerValThrSerAlaSerProAsnProLeuAlaThrGlyProLeu  
 610 620 630 640 650 660  
 GGTGTGTGCACCATGTCCCAGACCCAGCCTGACCTGGACCACCTGTACTCTCGCCACCG  
 GlyValCysThrMetSerGlnThrGlnProAspLeuAspHisLeuTyrSerProProPro  
 670 680 690 700 710 720  
 CCTCCTCCTTATTCTGGCTGTGCAGGAGACCTCTACCAGGACCCTTCTGCGTTCCCTG  
 ProProProProTyrSerGlyCysAlaGlyAspLeuTyrGlnAspProSerAlaPheLeu

FIGURE 3.2

SUBSTITUTE SHEET

730 740 750 760 770 780  
 TCAGCAGCCACCACCTCCACCTCTTCTCTGGCCTACCCACCACCTCCTTCCTATCCA  
 SerAlaAlaThrThrSerThrSerSerSerLeuAlaTyrProProProProSerTyrPro  
 790 800 810 820 830 840  
 TCCCCCAAGCCAGCCACGGACCCAGGTCTCTTCCCAATGATCCCAGACTATCCTGGATTCT  
 SerProLysProAlaThrAspProGlyLeuPheProMetIleProAspTyrProGlyPhe  
 850 860 870 880 890 900  
 TTTCCATCTCAGTGCCAGAGAGACCTACATGGTACAGCTGGCCAGACCGTAAGCCCTTT  
 PheProSerGlnCysGlnArgAspLeuHisGlyThrAlaGlyProAspArgLysProPhe  
 910 920 930 940 950 960  
 CCCTGCCCCACTGGACACCTGCGGGGTGCCCCCTCCACTCACTCCACTCTTACAATCCGT  
 ProCysProLeuAspThrLeuArgValProProProLeuThrProLeuSerThrIleArg  
 970 980 990 1000 1010 1020  
 AACTTTACCCTGGGGGGCCCCAGTGCTGGGATGACCGGACCAGGGGCCAGTGGAGGCAGC  
 AsnPheThrLeuGlyGlyProSerAlaGlyMetThrGlyProGlyAlaSerGlyGlySer  
 1030 1040 1050 1060 1070 1080  
 GAGGGACCCCGGCTGCCTGGTAGCAGCTCAGCAGCAGCAGCAGCCGCCGCCGCCGCCGCC  
 GluGlyProArgLeuProGlySerSerSerAlaAlaAlaAlaAlaAlaAlaAlaAla

FIGURE 3.3

**THIS PAGE BLANK (USPTO)**

SUBSTITUTE SHEET

1090 1100 1110 1120 1130 1140  
 TATAACCCACACCACCTGCCACTGCGGCCCATTTCTGAGGCCTCGCAAGTACCCCAACAGA  
 TyrAsnProHisHisLeuProLeuArgProIleLeuArgProArgLysTyrProAsnArg  
 1150 1160 1170 1180 1190 1200  
 CCCAGCAAGACGCCGGTGACGAGAGGCCCTACCCGTGCCCAGCAGAAGGCTGCGACCGG  
 ProSerLysThrProValHisGluArgProTyrProCysProAlaGluGlyCysAspArg  
 1210 1220 1230 1240 1250 1260  
 CGGTTCTCCCGCTCTGACGAGCTGACACGGCACATCCGAATCCACACTGGGCATAAGCCC  
 ArgPheSerArgSerAspGluLeuThrArgHisIleArgIleHisThrGlyHisLysPro  
 1270 1280 1290 1300 1310 1320  
 TTCCAGTGTCGGATCTGCATGCGCAACTTCAGCCGAGTGACCACCTCACCACCCATATC  
 PheGlnCysArgIleCysMetArgAsnPheSerArgSerAspHisLeuThrThrHisIle  
 1330 1340 1350 1360 1370 1380  
 CGCACCCACACCGGTGAGAAGCCCTTCGCCTGTGACTACTGTGGCCGAAAGTTTGCCCGG  
 ArgThrHisThrGlyGluLysProPheAlaCysAspTyrCysGlyArgLysPheAlaArg  
 1390 1400 1410 1420 1430 1440  
 AGTGATGAGAGGAAGCGCCACACCAAGATCCACCTGAGACAGAAAGAGCGGAAAAGCAGT  
 SerAspGluArgLysArgHisThrLysIleHisLeuArgGlnLysGluArgLysSerSer

FIGURE 3.4

SUBSTITUTE SHEET

1450 1460 1470 1480 1490 1500  
 GCCCCCTCTGCATCGGTGCCAGCCCCCTCTACAGCCTCCTGCTCTGGGGGCGTGACAGGCC  
 AlaProSerAlaSerValProAlaProSerThrAlaSerCysSerGlyGlyValGlnAla  
 1510 1520 1530 1540 1550 1560  
 TGGGGGTACCCTGTGCAGCAGTAACAGCAGCAGTCTTGCGGAGGGGCGCTCGCCCCCTTG  
 TrpGlyTyrProValGlnGlnEnd  
 1570 1580 1590 1600 1610 1620  
 CTCCTCTCGGACCCGGACACCTTGAGATGAGACTCAGGCTGATACACCAGCTCCCAAAGG  
 1630 1640 1650 1660 1670 1680  
 TCCCGGAGGCCCTTTGTCCACTGGAGCTGCACAACAAACACTACCACCCTTTCTGTCC  
 1690 1700 1710 1720 1730 1740  
 TCTCTCCCTTTGTTGGGCAAAGGGCTTTGGTGGAGCTAGCACTGCCCCCTTTCCACCTAG  
 1750 1760 1770 1780 1790 1800  
 AAGCAGGTTCTTCCTAAACTTAGCCATTCTAGTCTCTTAGGTGAGTTGACTATCAA

FIGURE 3.5

**THIS PAGE BLANK (USPTO)**

1810 1820 1830 1840 1850 1860  
CCCAAGGCAAAGGGGAGGCTCAGAAGGAGGTGGTGTGGGGATCCCCTGGCCAAGAGGGCT

1870 1880 1890 1900 1910 1920  
GAGGTCTGACCCTGCTTTAAAGGGTTGTTGACTAGGTTTGTCTACCCCACTTCCCCTTA

1930 1940 1950 1960 1970 1980  
TTTTGACCCATCACAGGTTTTTGACCCTGGATGTCAGAGTTGATCTAAGACGTTTTCTAC

1990 2000 2010 2020 2030 2040  
AATAGGTTGGGAGATGCTGATCCCTTCAAGTGGGGACAGCAAAAAGACAAGCAAAACTGA

2050 2060 2070 2080 2090 2100  
TGTGCACTTTATGGCTTGGGACTGATTTGGGGGACATTGTACAGTGAGTGAAGTATAGCC

2110 2120 2130 2140 2150 2160  
TTTATGCCACACTCTGTGGCCCTAAAATGGTGAATCAGAGCATATCTAGTTGTCTCAACC

FIGURE 3.6

2170 2180 2190 2200 2210 2220  
CTTGAAGCAATATGTATTATATACTCAGAGAACAGAAGTGCAATGTGATGGGAGGAACGT

2230 2240 2250 2260 2270 2280  
AGCAATATCTGCTCCTTTTCGAGTTGTTTGAGAAATGTAGGCTATTTTTTCAGTGTATAT

2290 2300 2310 2320 2330 2340  
CCACTCAGATTTTGTGTATTTTGTATGTACCCACACTGTTCTCTAAATTCTGAATCTTTG

2350 2360 2370 2380 2390 2400  
GGAAAAAATGTAAAGCATTATGATCTCAGAGGTTAACTTATTTAAGGGGGATGTACATA

2410 2420 2430 2440 2450 2460  
TTCTCTGAAACTAGGATGCATGCAATTGTGTTGGAAGTGTCTTGGTTCGCCTTGTGTGAT

2470 2480 2490 2500 2510 2520  
GTAGACAAATGTTACAAGGCTGCATGTAAATGGGTTGCCTTATTATGGAGAAAAAATCA

FIGURE 3.7

**THIS PAGE BLANK (USPTO)**



2530 2540 2550 2560 2570 2580  
CTCCCTGAGTTT TAGTATGGCTGTATATTTATGCCTATTAATATTTCAAATTTTTTTTAG

2590 2600 2610 2620 2630 2640  
AGTATATTTTTGTATGCTTTGTTTTGTGACTTAAAAGTGTTACCTTTGTAGTCAAATTC

2650 2660 2670 2680 2690 2700  
AGATAAGAATGTACATAATGTTACCGGAGCTGANNNTTGTGGTCATTAGCTCTTAATA

2710 2720 2730 2740 2750 2760  
GTTGTGAAAAATAAATCTATTCTAACGCAAACCACTAACTGAAGTTCAGATATAATGG

2770 2780 2790 2800 2810  
ATGGTTTGTGACTATAGTGTAATAAATACTTTTCAACAAAAAAAAAAAAAAAAAAAA

FIGURE 3.8

-935  
ACGGAGGGAA TAGCCTTTCC ATTCTGGGTG BTGCATTGGA ABCCCCAGGC TCTAANACCC

-875  
CCAACCTACT GACTGGTGGC CBAATATGCA CCCGACTGCT AGCTAGGCAG TGTCCCAAGA

-815  
ACCAATAGCC AAATGTCTTG GCCTCAGTTT TCCCGBTBAC ACCTGGAAG TGACCCTGCC

-753  
ATTAGTAGAG GCTCAGGTCA GGGCCCCGCC TCTCCTGGGC GGCCTCTGCC CTAGCCCGCC

-695  
CTGCCGCTCC TCCTCTCCGC AGGCTCGCTC CCACGGTCCC CBAATGGGC GGGTGAGCCC

-635  
AGGATGACGG CTGTAGAACC CCGGCTGAC TCGCCCTCGC CCCCBCGCCB GGCCTGGGCT

-575  
TCCCTAGGCC AGCTCGCACC CCGGGGCCGT CGBAGCCGCC BCBCGCCAG CTCTACGCC

-515  
CTGGCCCTCC CCACGCBBGC BTCCCCACT CCGCGCCGCB CTCAGGCTCC CAGTTGGGAA

-455  
CCAAGGAGGB GBAATATGGG GGGGGGGGTG TCGCCGACC CGBAACGCC ATATAAGGAG

-395  
CAGGAAGGAT CCCCCGCCGG AACAGACCTT ATTGGGCG CBCCTTATAT GGATGGCTC

FIGURE 4.1

**THIS PAGE BLANK (USPTO)**

20/21

21/21

SUBSTITUTE SHEET

```

-335          -276
AATATGCCCC TGCCGCTTCC GGTCTGCGA GGAAGGCGCA GCGGGGTTG GGGCGGGGGC

-275          -216
AAGCTGGGAA CTCCAGGCGC CTGCCCCGGG AGGCACTGC TGTGTTCCA ATACTAGGCT
SmaI

-215          -156
TTCCAGGAGC CTGAGCGCTC GCGATGCCGG AGCGGGTCGC AGGGTGGAGG TGCCCAACCAC

-155          -96
TCTTGGATGG GAGGGCTTCA CGTCACTCCG GGTCTCTCCG GCGGGTCCCT CCATATTAGG

-95          -36
GCTTCTGCT TCCCATATAT GGCATGTAC GTCACGGCGG AGGCGGGCCC GTGCTGTTCC

-35          +25
AGACCCCTTC AATAAGGCC GATTCGGGGA GTCGCGAGAG ATCCACGCGC GCAGAACTTG

+26          +85
GGGAGCCGCC GCGCGATTG GCGCGCGCG CCAGCTTCCG CCGCCGCAAG ATCGGCCCTT
29-mar

+86          +145
GCCCCAGCCT CCGCGGCGAG CCTGCTTCCA CCACGGGCGG CGGTACCGC CAGCCTGGGG

+146          +205
GCCCCACTAC ACTCCCCGCA GTGTGCCCCG GCACCCCGCA TGTAACCCGG CCAACCCCGG

+206          +265
GCGAGTGTGC CCTCAGTAGC TTCGCCCCCG GGTGCGGCGC ACCACCAAC ATCAGTTCTC
SmaI
    
```

FIGURE 4.2




FIGURE 5

SUBSTITUTE SHEET

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/01473

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (In several classification symbols apply, indicate all) According to International Patent Classification (IPC) or to both National Classification and IPC CO7H 15/12, C12P 21/00, 19/34; C12N 15/00, 7/00, 1/20; C12Q 1/68; CO7K 13/00	
<b>II. FIELDS SEARCHED</b> Minimum Documentation Searched: Classification Symbols US 536/27; 435/68, 91, 172.1, 172.3, 320, 252.3, 6; 530/550, 387	
Documentation Searched either than Minimum Documentation to the Extent that such Documents are included in the Fields Searched: CAS database (1967-1989) keywords: finger/protein/motif early growth regulatory/gene/expression/sequence	
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> Category: Citation of Document, with indication, where appropriate, of the relevant passages Relevant to Claim No. 13	1-5, 8-10 6, 7, 11, 12 14-16 1-5, 8-10 6, 7, 11, 12, 14-16 1-5, 7-11 6, 12, 14-16
X Y X Y X Y	Chavrier, P. et al (January 1988) EMBO Journal, Volume 7: 29-35; "A gene encoding a protein with zinc fingers is activated during G <sub>0</sub> /G <sub>1</sub> transition in cultured cells. See entire document. Chowdhury, K. et al (March 1988) Cell, Volume 48: 771-778; "A Multigene family encoding several finger structures is present and differentially active in mammalian genomes". See entire document. Lau, L. et al (March 1987) PNAS, Volume 84: 1182-1186; "Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc. See entire document
<b>IV. CERTIFICATION</b> Date of the Actual Completion of the International Search 27 June 1989 International Searching Authority ISA US Signature of Authorized Officer Anne Brown Date of Filing of this International Search Report 24 AUG 1989	

Form PCT/ISA/210 (second sheet) (Rev. 11-87)

International Application No. PCT/US89/01473

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

P, Y Pannuti, A. et al (May 1988) Nucleic Acids Res., Volume 16: 4227-4237 "Isolation of CDNAs encoding finger proteins and measurement of the corresponding mRNA levels during myeloid terminal differentiation" See entire document. P, Y Almendrol et al (May 1988) Mol Cell Biol, Vol. 8: 2140-2148 "Complexity of the Early Genetic Response to Growth Factors in Mouse Fibroblasts". See entire document.	1-12, 14-16 1-12, 14-16
<b>V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE</b> This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: 1. Claim numbers _____, because they relate to subject matter is not required to be searched by this Authority, namely: 2. Claim numbers _____, because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out in, specifically: 3. Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a). <b>VII. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING</b> This International Searching Authority found multiple inventions in this International application as follows: See attached sheet	
1. <input type="checkbox"/> As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application. 2. <input type="checkbox"/> As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims: 3. <input checked="" type="checkbox"/> No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: 1-12, 14-16 4. <input type="checkbox"/> As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not make payment of any additional fee. Remark on Protest: <input type="checkbox"/> The additional search fees were accompanied by applicant's protest. <input type="checkbox"/> No protest accompanied the payment of additional search fees.	

Form PCT/ISA/210 (second sheet) (Rev. 11-87)

ATTACHMENT TO PCT/ISA/210  
VI. OBSERVATION WHERE UNITY OF INVENTION IS LACKING

I. Claims 1-12, and 14-16 are drawn to EGR DNA sequence, vector or cell containing it, transformed host, method of using vector or cell and a polypeptide.

II. Claim 13 is drawn to cell-free method of preparing an early growth regulatory protein.

III. Claims 17-19 are drawn to native EGR protein.

IV. Claims 20-23 are drawn to synthetic peptide fragment antigenically related to and containing homology to native EGR protein.

V. Claims 24-29 are drawn to antibodies to EGR, anti-bodies to region EGR, method of using antibody.

VI. Claim 30 is drawn to method of detecting mRNA.

VII. Claim 31 is drawn to method of detecting DNA.

VIII. Claim 32 is drawn to method of diagnosis.

The claims do not embrace one single general inventive concept as defined in Rule 13.

Groups I, II, IV and V contain claims directed to distinct chemical entities. These are a gene and a protein coded for by that gene, a native EGR protein, a synthetic peptide fragment, antibodies which bind to EGR proteins. Groups II, VI, VII and VIII are directed to alternative uses for the nucleotide defined in Group I.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**